The billion-dollar peptide craze could get even bigger

In the US, the peptide craze, which has already created a billion-dollar market, may get an additional boost. The administration, associated with the Make America Healthy Again (MAHA) movement, is pushing to review regulatory restrictions on certain peptide drugs often used in the context of recovery, weight loss and overall wellness.

According to xrust analysts, the global market for therapeutic peptides is valued at approximately $140 billion in 2025 and could reach $294 billion by 2033 under favorable conditions.

Role of RFK Jr. and MAHA in growing popularity

Secretary of Health Robert F. Kennedy Jr. is an outspoken supporter of peptides, saying he has used some of them himself to treat injuries. His stance and initiatives to ease previous restrictions have contributed to a surge in interest in these substances among consumers and suppliers.

“I’m a big fan of peptides,” Kennedy noted in an interview, highlighting the potential for their wider availability through regulated channels such as compounding pharmacies.

Context and current challenges

Peptides are short chains of amino acids that, in specific forms, are used for a variety of purposes, from supporting muscle growth to promoting healing. In recent years, their popularity has skyrocketed thanks to the influence of influencers, fitness communities and wellness trend supporters. However, many of them have not gone through the full FDA approval process as drugs, leading to the development of gray and black markets.

In 2023, the Biden administration tightened rules for compounding pharmacies, which critics of the MAHA initiatives say pushed users toward less controlled sources. The FDA is now planning to hold expert panels to evaluate the safety and effectiveness of a number of peptides.

Possible consequences of regulation

class=»notranslate»>__GTAG7__ Upcoming changes could legalize the production of certain peptides in compounding pharmacies, potentially expanding access for consumers and creating new opportunities for telemedicine and specialty clinics. Analysts predict significant market growth if regulations are relaxed.

At the same time, FDA scientists and experts highlight the lack of reliable data on the long-term effectiveness and safety of many substances. This creates a tension between the desire for greater availability and the need to minimize health risks. The final decisions could impact not only the US market, but also global trends in personalized medicine and prevention.

News feed https://www.bloomberg.com

Xrust The billion-dollar peptide craze could get even bigger